FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial. PMID 42015666 · Int J Cancer · 2026-Sep-01 The record describes the CAP randomised trial, which is a large, randomized screening trial for prostate cancer. While it is an oncology, human, randomized trial with long-term time-to-event analysis, it does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III trial of a drug-containing intervention. The intervention is a one-off PSA screening test, not a therapeutic drug. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. PMID 40956129 · Int J Cancer · 2026-Sep-01 The record describes a biomarker and machine learning analysis for predicting prostate cancer aggressiveness and mortality. It is not a randomized controlled trial, does not involve a drug intervention, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, Kaplan-Meier, HR) from a clinical trial. It is excluded based on these criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial. PMID 42208702 · Magn Reson Imaging · 2026-Oct The abstract describes a secondary biomarker analysis (imaging correlation) from a COG phase III trial, not the primary report of the trial's efficacy results. While it references a phase III trial and EFS, the abstract itself is not the original formal report of the randomized trial's primary efficacy outcome, and key eligibility criteria (explicit randomization, specific drug intervention) are not established in the provided text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial. PMID 42225236 · Ann Oncol · 2026-May-31 Study is a randomized trial in human oncology with a drug intervention and time-to-event endpoints (DFS, OS, recurrence). Phase is not explicitly stated in the record, but it is a definitive randomized trial with primary results, meeting eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. PMID 42223087 · N Engl J Med · 2026-May-31 Meets all eligibility criteria: phase 3, randomized, human oncology trial with a drug intervention and primary time-to-event endpoint (EFS). |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. PMID 42217582 · Ann Oncol · 2026-May-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The impact of an artificial intelligence (AI)-assisted education program on mental health, social support and quality of life in older individuals with head and neck cancer: study protocol of a randomized controlled trial. PMID 42215892 · BMC Geriatr · 2026-May-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. PMID 42212913 · N Engl J Med · 2026-May-29 The record explicitly describes a phase 3 international trial with random assignment (1:1), a primary time-to-event efficacy endpoint (PFS with HR), a drug-containing intervention (sunvozertinib vs. chemotherapy), and presents the original primary result of the trial. It meets all criteria for inclusion. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Lifestyle Program for Breast Cancer Improves Body Composition, Fitness, and Patient-Reported Outcomes: A Randomized Clinical Trial. PMID 42279341 · Cancers (Basel) · 2026-May-27 The record describes a randomized trial of a non-drug lifestyle intervention in oncology, reporting secondary patient-reported and physiological outcomes. It does not meet the required criteria for a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin-naïve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.009. PMID 42203610 · Eur Urol Focus · 2026-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.009. PMID 42203609 · Eur Urol Focus · 2026-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial. PMID 42202247 · JCO Oncol Pract · 2026-May-27 The study is a randomized Phase III trial in oncology patients with drug intervention, but it lacks a primary time-to-event efficacy endpoint. The primary endpoint is a safety/comparative effectiveness endpoint (adverse events), not a survival or progression metric. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor DNA-based assessment of disease progression after liver resection or transplantation for metastatic colorectal cancer or hepatocellular carcinoma-study protocol for a randomized, controlled trial. PMID 42185926 · Trials · 2026-May-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial. PMID 42186031 · J Ovarian Res · 2026-May-25 The study is a single-arm, open-label phase IIIb trial, not a randomized controlled trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis. PMID 42185290 · Nat Commun · 2026-May-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma. PMID 42184925 · Ann Hepatol · 2026-May-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND-XR. PMID 42179065 · Andrology · 2026-May-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A comparative analysis of parametric, semiparametric and machine learning models for survival prediction. PMID 42178520 · BMC Med Res Methodol · 2026-May-25 The record is a methodological comparative analysis of survival models using data from a Phase III trial, not an original report of a randomized trial with a drug intervention and primary efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| How can a remotely delivered, personalised physical activity intervention for people with high risk of breast, lung and bowel cancer recurrence be implemented in England? Protocol for a mixed-methods process evaluation embedded in a feasibility basket trial. PMID 42192622 · BMJ Open · 2026-May-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Randomized Controlled Trial to Evaluate the Efficacy and Safety of Silicone-Covered Metallic Mesh Stent Compared to Conventional Polymeric Stent in Malignant Ureteral Obstruction Patients. PMID 42178753 · J Endourol · 2026-May-24 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer. PMID 42178168 · Cancer Sci · 2026-May-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Radioligand Therapy Hormone Combinations and the ENZA-p Trial. PMID 42177103 · Eur Urol Focus · 2026-May-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of a Personalized Mobile Health Intervention Using Artificial Intelligence (the WARIFA App) Versus a Nonpersonalized Intervention on User-Defined Objectives, Healthy Lifestyles, and Management of Type 1 Diabetes (T1D): Protocol for a Randomized Controlled Trial. PMID 42172625 · JMIR Res Protoc · 2026-May-22 The record describes a protocol for a randomized controlled trial evaluating a mobile health app (WARIFA) with AI-driven personalized messages versus a nonpersonalized version. It is not an oncology trial, does not involve a drug intervention, does not report time-to-event efficacy data (primary endpoint is a Likert-scale goal assessment), and results are pending (data analysis ongoing). Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19-09, CONPELAN Study. PMID 42168759 · Head Neck · 2026-May-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial. PMID 42168180 · Nat Commun · 2026-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin-naïve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.011. PMID 42168001 · Eur Urol · 2026-May-21 Insufficient metadata to confirm human subjects, drug intervention, time-to-event efficacy endpoint, or original result report status. Title indicates a phase 3 RCT in oncology, but the record is a reply letter with no abstract, making eligibility criteria unverifiable. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial. PMID 42166768 · JMIR Mhealth Uhealth · 2026-May-21 The study is an original randomized controlled trial in multiple myeloma survivors, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified, likely early or supportive care), it does not have a drug-containing intervention (exercise rehabilitation only), and its primary/secondary endpoints are not time-to-event efficacy outcomes (OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial comparing robotic NOSES versus robotic TME for Mid-rectal cancer: short-term oncological and perioperative outcomes. PMID 42162355 · J Robot Surg · 2026-May-21 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Perioperative nebulized budesonide and L-Cysteine reduce pulmonary complications after posterior skull base tumor resection: a randomized controlled trial. PMID 42163118 · BMC Anesthesiol · 2026-May-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. PMID 41996652 · J Clin Oncol · 2026-May-20 The record is an editorial/commentary analyzing the results of a randomized trial (LIBRETTO-431) and the issue of crossover. It is not the original, formal-result report of the trial itself. While the discussed trial is oncology, human, randomized, involves a drug intervention, and has time-to-event endpoints, the provided metadata does not confirm the trial phase as Phase III/IIIb or Phase II/III, and the article type is a secondary analysis/commentary, not the primary result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial. PMID 42162664 · Ann Oncol · 2026-May-19 The study is a randomized Phase III trial in human oncology with a drug intervention, but its primary efficacy endpoint is pathologic complete response (pCR), which is a categorical binary outcome, not a time-to-event endpoint. No time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) or associated Kaplan-Meier/HR results are reported in the provided abstract. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cryoablation for early-stage invasive breast cancer: pathologic and imaging outcomes from the prospective FIRST trial. PMID 42157305 · Breast Cancer Res · 2026-May-19 The study is a prospective, non-randomized, single-arm Phase II trial evaluating cryoablation for early-stage breast cancer. It does not meet key eligibility criteria: it is not randomized, is Phase II (not Phase III/IIIb or Phase II/III), uses a non-drug intervention (cryoablation), and its primary efficacy endpoint is pathologic ablation rate, not a time-to-event outcome. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Artificial intelligence-assisted integrated care to promote colonoscopy uptake (AICC) in China: study protocol for a cluster randomized controlled trial. PMID 42152022 · Trials · 2026-May-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry. PMID 42150842 · RMD Open · 2026-May-18 The study is a registry-based observational analysis of real-world effectiveness in rheumatoid arthritis, not an oncology trial. It is not a randomized controlled trial reporting results from a Phase III/IIIb or Phase II/III drug intervention trial with a primary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial. PMID 42149133 · Clin Cancer Res · 2026-May-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). PMID 42142212 · Rheumatol Ther · 2026-May-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. PMID 42140950 · Nat Commun · 2026-May-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the Organ Preservation in Patients With Rectal Adenocarcinoma Trial. PMID 42142103 · Int J Radiat Oncol Biol Phys · 2026-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62). PMID 42140839 · Int J Gynecol Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters. PMID 42138077 · J Clin Invest · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. PMID 42135177 · Eur Urol · 2026-May-15 The study is an original, randomized trial in oncology with a time-to-event endpoint, but it compares two surgical techniques (non-drug intervention) and does not meet the required Phase III/IIIb or Phase II/III evidence criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site. PMID 41935492 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. PMID 41921365 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629). PMID 41905242 · Eur J Cancer · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. PMID 41779000 · Clin Cancer Res · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment. PMID 41671078 · Clin Cancer Res · 2026-May-15 The report is an original randomized trial, but the abstract focuses on a secondary/prognostic biomarker analysis (ctDNA) rather than the primary efficacy comparison of the intervention. The required phase (III/IIIb or II/III) is not explicitly established in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results. PMID 41632450 · Clin Cancer Res · 2026-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). PMID 41609523 · Clin Cancer Res · 2026-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study. PMID 42150214 · Breast · 2026-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Investigation of oral bromelain supplementation on the healing of skin flap reconstruction after Mohs micrographic surgery (MMS) for non-melanoma skin cancers (NMSCs). PMID 42135693 · BMC Surg · 2026-May-14 The study is a randomized trial in an oncology context (non-melanoma skin cancer) with a drug/intervention (bromelain), but the primary endpoint is time to suture removal, which is a wound-healing measure, not a standard oncological time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
第 1 / 179 页
下一页